On November 4, 2020 Orexo reported that In connection with the publication of the Interim Report for Q3 2020, an updated guiding was shared for the full year 2020 (Press release, Orexo, NOV 4, 2020, View Source;q3-2020-interim-report–zubsolv-guiding-2020-301166246.html [SID1234569911]). For ZUBSOLV, net sales for Q4 2020 are expected to improve compared to Q3 2020, and net sales for 2020 will decline compared to 2019. Net sales and OPEX guiding are based on the exchange rate as of September 30, 2020. This information replaces corresponding information in the Interim Report published today at 8.00 am CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!